Experiencia y evidencia
Vacuna avalada por la evidencia científica
40 de años de investigación en colaboración con el CBM y Universidades españolas (UEx, UCM, UAB).
5 Artículos en revistas científicas de alto impacto
4 Comunicaciones Orales en congresos nacionales e internacionales
4 Pósters en congresos nacionales e internacionales.
Artículos
- Soto et al. 1998. American Society for Microbiology. Multicomponent Chimeric Antigen for serodiagnosis of Canine Visceral Leishmaniasis
- Almeida et al. 2022. Microorganisms. Seroprevalence and Risk Factors Associated with Leishmania Infection in Dogs from Portugal
- Cacheiro-Llaguno et al. 2019. Vaccine. Vaccination with LetiFend reduces circulating immune complexes in dogs experimentally infected with L. infantum
- Fernández-Cotrina et al. 2018. Vaccine. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend against canine leishmaniosis
- Carcelén et al. 2009. Vaccine. The Chimerical Multi-Component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection
Pósters
- Iniesta et al. 2016. SEVC. Vaccination With LetiFend®, A Novel Canine Leishmaniosis Vaccine, Does Not Interfere With Serological Diagnostic Tests
- Almeida et al. 2022. WorldLeish7. The Chimerical Multi-Component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection
- Miró et al. 2017. AMVAC. Estudio piloto multicéntricopost-autorización sobre la seguridad de la vacuna LetiFend®en perros en España
- Foj et al. 2019. GTA. ESTUDIO MULTICÉNTRICO PROSPECTIVO DE SEGUIMIENTO DE PERROS VACUNADOS CON LETIFEND®
Comunicaciones Orales
- Foj et al. 2019. WAAVP. Leishmaniosis in Vaccinated dogs. Clinical aspects
- Maia et al. 2022. ALIVE. National seroepidemiological survey of Leishmania infection in dogs from Portugal- Preliminary results
- Foj et al. 2022. ALIVE Multicentre follow-up field study of dogs vaccinated with LetiFend® (2017-2020)
- Montoya et al. 2022. ALIVE. Safety and antibody response elicited by LetiFend in two multicenter post-authorization studies in Spain